Groups of coevolving positions provide drug resistance to Mycobacterium tuberculosis: A study using targets of first-line antituberculosis drugs

2019 ◽  
Vol 53 (3) ◽  
pp. 197-202 ◽  
Author(s):  
Sharad Vats ◽  
Asheesh Shanker
2009 ◽  
Vol 53 (9) ◽  
pp. 3799-3802 ◽  
Author(s):  
Niaz Banaei ◽  
Eleanor Z. Kincaid ◽  
S.-Y. Grace Lin ◽  
Edward Desmond ◽  
William R. Jacobs ◽  
...  

ABSTRACT Malachite green, a synthetic antimicrobial dye, has been used for over 50 years in mycobacterial culture medium to inhibit the growth of contaminants. The molecular basis of mycobacterial resistance to malachite green is unknown, although the presence of malachite green-reducing enzymes in the cell envelope has been suggested. The objective of this study was to investigate the role of lipoproteins in resistance of Mycobacterium tuberculosis to malachite green. The replication of an M. tuberculosis lipoprotein signal peptidase II (lspA) mutant (ΔlspA::lspA mut) on Middlebrook agar with and without 1 mg/liter malachite green was investigated. The lspA mutant was also compared with wild-type M. tuberculosis in the decolorization rate of malachite green and sensitivity to sodium dodecyl sulfate (SDS) detergent and first-line antituberculosis drugs. The lspA mutant has a 104-fold reduction in CFU-forming efficiency on Middlebrook agar with malachite green. Malachite green is decolorized faster in the presence of the lspA mutant than wild-type bacteria. The lspA mutant is hypersensitive to SDS detergent and shows increased sensitivity to first-line antituberculosis drugs. In summary, lipoprotein processing by LspA is essential for resistance of M. tuberculosis to malachite green. A cell wall permeability defect is likely responsible for the hypersensitivity of lspA mutant to malachite green.


2006 ◽  
Vol 50 (8) ◽  
pp. 2820-2823 ◽  
Author(s):  
Igor Mokrousov ◽  
Wei Wei Jiao ◽  
Gui Zhi Sun ◽  
Jia Wen Liu ◽  
Violeta Valcheva ◽  
...  

ABSTRACT We compared the population structure and drug resistance patterns of the Mycobacterium tuberculosis strains currently circulating in the Beijing area of China. One hundred thirteen of 123 strains belonged to the Beijing family genotypes defined by spoligotyping. The Beijing genotype strains were further subdivided into old and modern sublineages on the basis of NTF locus analysis. A stronger association with resistance to the more recently introduced antituberculosis drugs has been observed for old versus modern strains of the Beijing genotype, suggesting that its different sublineages may differ in their mechanisms of adaptation to drug selective pressure.


Lung India ◽  
2012 ◽  
Vol 29 (3) ◽  
pp. 227 ◽  
Author(s):  
Sarala Menon ◽  
Chhaya Chande ◽  
Sunil Lilani ◽  
Ameeta Joshi ◽  
Renu Bharadwaj ◽  
...  

2020 ◽  
Author(s):  
Guo Liang Gan ◽  
Matthew Nguyen ◽  
Elijah Willie ◽  
Brian Lee ◽  
Cedric Chauve ◽  
...  

AbstractThe efficacy of antibiotic drug treatments in tuberculosis (TB) is significantly threatened by the development of drug resistance. There is a need for a robust diagnostic system that can accurately predict drug resistance in patients. In recent years, researchers have been taking advantage of whole-genome sequencing (WGS) data to infer antibiotic resistance. In this work we investigate the power of machine learning tools in inferring drug resistance from WGS data on three distinct datasets differing in their geographical diversity.We analyzed data from the Relational Sequencing TB Data Platform, which comprises global isolates from 32 different countries, the PATRIC database, containing isolates contributed by researchers around the world, and isolates collected by the British Columbia Centre for Disease Control in Canada. We predicted drug resistance to the first-line drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin. We focused on the genes which previous evidence suggests are involved in drug resistance in TB.We called single-nucleotide polymorphisms using the Snippy pipeline, then applied different machine learning models. Following best practices, we chose the best parameters for each model via cross-validation on the training set and evaluated the performance via the sensitivity-specificity tradeoffs on the testing set.To the best of our knowledge, our study is the first to predict antibiotic resistance in TB across multiple datasets. We obtained a performance comparable to that seen in previous studies, but observed that performance may be negatively affected when training on one dataset and testing on another, suggesting the importance of geographical heterogeneity in drug resistance predictions. In addition, we investigated the importance of each gene within each model, and recapitulated some previously known biology of drug resistance. This study paves the way for further investigations, with the ultimate goal of creating an accurate, interpretable and globally generalizable model for predicting drug resistance in TB.Author summaryDrug resistance in pathogenic bacteria such as Mycobacterium tuberculosis can be predicted by an application of machine learning models to next-generation sequencing data. The received wisdom is that following standard protocols for training commonly used machine learning models should produce accurate drug resistance predictions.In this paper, we propose an important caveat to this idea. Specifically, we show that considering geographical diversity is critical for making accurate predictions, and that different geographic regions may have disparate drug resistance mechanisms that are predominant. By comparing the results within and across a regional dataset and two international datasets, we show that model performance may vary dramatically between settings.In addition, we propose a new method for extracting the most important variants responsible for predicting resistance to each first-line drug, and show that it is to recapitulate a large amount of what is known about the biology of drug resistance in Mycobacterium tuberculosis.


2018 ◽  
Vol 62 (3) ◽  
Author(s):  
Catherine Vilchèze ◽  
John Kim ◽  
William R. Jacobs

ABSTRACT The treatment of drug-susceptible tuberculosis (TB) is long and cumbersome. Mismanagement of TB treatment can lead to the emergence of drug resistance in patients, so shortening the treatment duration could significantly improve TB chemotherapy and prevent the development of drug resistance. We previously discovered that high concentrations of vitamin C sterilize cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis . Here, we tested subinhibitory concentration of vitamin C in combination with TB drugs against M. tuberculosis in vitro and in a mouse model of M. tuberculosis infection. In vivo , we showed that the vitamin C level in mouse serum can be increased by intraperitoneal injection of vitamin C to reach vitamin C levels close to the concentrations required for activity in vitro . Although vitamin C had no activity by itself in M. tuberculosis -infected mice, the combination of vitamin C with the first-line TB drugs isoniazid and rifampin reduced the bacterial burden in the lungs of M. tuberculosis -infected mice faster than isoniazid and rifampin combined in two independent experiments. These experiments suggest that the addition of vitamin C to first-line TB drugs could shorten TB treatment. Vitamin C, an inexpensive and nontoxic compound, could easily be added to the TB pharmacopeia to substantially improve chemotherapy outcome, which would have a significant impact on the worldwide TB community.


Author(s):  
Nazlı Arslan ◽  
Müge Hacer Özkarataş ◽  
Nuran Esen ◽  
Aydan Özkütük

Objective: Tuberculosis retains its importance as the only infectious disease in the world that affects 10 million people and causes 1.5 million deaths per se. The major obstacle in the elimination and control of tuberculosis is the emergence and spread of resistant tuberculosis cases. It was aimed to determine the current Mycobacterium tuberculosis complex and its susceptibility to antituberculosis drugs at Dokuz Eylül University Hospital. Method: In our study, the results of all samples sent between January 2013 and November 2019 were examined retrospectively for the presence of M. tuberculosis complex and drug susceptibility results. The samples were cultured in Löwenstein Jensen media and BACTEC MGIT 960 system. Drug susceptibility testing was performed with the BACTEC MGIT 960 SIRE kit in accordance with the recommendations of the manufacturer. Results: In a total of 473 (2.2%) of 21620 specimens M. tuberculosis complex was reproduced. The samples were classified as pulmonary (n:300; 63.4%) and extrapulmonary (n:173; 36.6%), samples. When repeated samples of the same patient, were excluded, positive culture test results were determined in a total of 365 patients. Susceptibility to all primary antituberculosis drugs was shown in 275 of 321 (85.7%) patients, while total rates of resistance to streptomycin, isoniazid, rifampicin and ethambutol were found in respective number of patients as follows: (n:24 (7.5%), 22 (6.8%), (n:7; 2.2%) and (n:2; 0.6%). The rate of MDR was 0.6% in 2 patients. Conclusion: In our hospital, streptomycin is the first-line antituberculosis drug with the highest resistance rate. All susceptibility rates were seen lower than the data reported in Turkey Tuberculosis Control Report and other studies of Turkey. Implementing drug surveillance program plays an important role for maintaining these low rates and for the management of tuberculosis.


Sign in / Sign up

Export Citation Format

Share Document